Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

INTRODUCTION: The API AutosomalDominant AD (ADAD) Colombia Trial is a placebo‐controlled clinical trial of crenezumab in 252 cognitively unimpaired 30 to 60‐year‐old Presenilin 1 (PSEN1) E280A kindred members, including mutation carriers randomized to active treatment or placebo and non‐carriers who...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Alzheimers Dement
Main Authors: Rios‐Romenets, Silvia, Lopera, Francisco, Sink, Kaycee M., Hu, Nan, Lian, Qinshu, Guthrie, Heather, Smith, Jillian, Cho, William, Mackey, Howard, Langbaum, Jessica B., Thomas, Ronald G., Giraldo‐Chica, Margarita, Tobon, Carlos, Acosta‐Baena, Natalia, Muñoz, Claudia, Ospina, Paula, Tirado, Victoria, Henao, Eliana, Bocanegra, Yamile, Chen, Kewei, Su, Yi, Goradia, Dhruman, Thiyyagura, Pradeep, VanGilder, Paul S., Luo, Ji, Ghisays, Valentina, Lee, Wendy, Malek‐Ahmadi, Michael H., Protas, Hillary D., Chen, Yinghua, Quiroz, Yakeel T., Reiman, Eric M., Tariot, Pierre N.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Featured Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7819133/
https://ncbi.nlm.nih.gov/pubmed/32418361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/alz.12109
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados